Development of pegylated liposomal vincristine using novel sulfobutyl ether cyclodextrin gradient: Is improved drug retention sufficient to surpass DSPE-PEG-induced drug leakage?

Journal of Pharmaceutical Sciences

Volumn 100, Issue 7, 2011, Pages 2835-2848

  Cui, Jingxia ^a   Li, Chunlei ^b,c,d   Wang, Caixia ^b,c,d   Li, Yanhui ^b,c,d   Zhang, Lan ^b,c,d   Zhang, Li ^b,c,d   Xiu, Xian ^b,c,d   Li, Yongfeng ^b,c,d   Wei, Na ^b,c,d  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd   (China)

^c State Key Lab of New Pharmaceutical Preparations and Excipients   (China)

^d Hebei Pharmaceutical Engineering and Technology Research Center   (China)

Author keywords

Circulation time; Complexation; Drug loading; Drug targeting; Efficacy; Liposomes; Pharmacokinetics; Sulfobutyl ether cyclodextrin; Toxicity; Vincristine

Indexed keywords

CYCLODEXTRIN; MACROGOL; VINCA ALKALOID; VINCRISTINE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL VACUOLE; CONTROLLED STUDY; DRUG HALF LIFE; DRUG RELEASE; DRUG RETENTION; HUMAN; IN VIVO STUDY; MOUSE; NONHUMAN;

EID: 79955597637     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22496     Document Type: Article

References (41)

1. Johnson IS, Armstrong JG, Gorman M, Burnett JP, Jr. 1963. The vinca alkaloids: A new class of oncolytic agents. Cancer Res 23:1390-1427.
2. Gidding CE, Kellie SJ, Kamps WA, de Graaf SS. 1999. Vincristine revisited. Crit Rev Oncol Hematol 29(3):267-287.
3. Camplejohn RS. 1980. A critical review of the use of vincristine (VCR) as a tumour cell synchronizing agent in cancer therapy. Cell Tissue Kinet 13(3):327-335.
4. Legha SS. 1986. Vincristine neurotoxicity. Pathophysiology and management. Med Toxicol 1(6):421-427.
5. Rosenthal S, Kaufman S. 1974. Vincristine neurotoxicity. Ann Intern Med 80(6):733-737.
6. Sathiapalan RK, El-Solh H. 2001. Enhanced vincristine neurotoxicity from drug interactions: Case report and review of literature. Pediatr Hematol Oncol 18(8):543-546.
7. Mayer LD, Bally MB, Loughrey H, Masin D, Cullis PR. 1990. Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res 50(3):575-579.
8. Gabizon A, Shmeeda H, Barenholz Y. 2003. Pharmacokinetics of pegylated liposomal doxorubicin: Review of animal and human studies. Clin Pharmacokinet 42(5):419-436.
9. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F, Huang A, Barenholz Y. 1994. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54(4):987-992.
10. Kanter PM, Klaich GM, Bullard GA, King JM, Bally MB, Mayer LD. 1994. Liposome encapsulated vincristine: Preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice, rats and dogs. Anticancer Drugs 5(5):579-590.
11. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. 1999. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51(4):691-743.
12. Kirby C, Gregoriadis G. 1983. The effect of lipid composition of small unilamellar liposomes containing melphalan and vincristine on drug clearance after injection into mice. Biochem Pharmacol 32(4):609-615.
13. Allen TM, Newman MS, Woodle MC, Mayhew E, Uster PS. 1995. Pharmacokinetics and anti-tumor activity of vincristine encapsulated in sterically stabilized liposomes. Int J Cancer 62(2):199-204.
14. Krishna R, Webb MS, St Onge G, Mayer LD. 2001. Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. J Pharmacol Exp Ther 298(3):1206-1212.
15. Wu NZ, Da D, Rudoll TL, Needham D, Whorton AR, Dewhirst MW. 1993. Increased microvascular permeability contributes to preferential accumulation of stealth liposomes in tumor tissue. Cancer Res 53(16):3765-3770.
16. Webb MS, Harasym TO, Masin D, Bally MB, Mayer LD. 1995. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer 72(4):896-904.
17. Noble CO, Guo Z, Hayes ME, Marks JD, Park JW, Benz CC, Kirpotin DB, Drummond DC. 2009. Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine. Cancer Chemother Pharmacol 64(4):741-751.
18. Boman NL, Masin D, Mayer LD, Cullis PR, Bally MB. 1994. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res 54(11):2830-2833.
19. Rodriguez MA, Pytlik R, Kozak T, Chhanabhai M, Gascoyne R, Lu B, Deitcher SR, Winter JN. 2009. Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: Report of the pivotal phase 2 study. Cancer 115(15):3475-3482.
20. Johnston MJ, Semple SC, Klimuk SK, Ansell S, Maurer N, Cullis PR. 2007. Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin. Biochim Biophys Acta 1768(5):1121-1127.
21. Boehlke L, Winter JN. 2006. Sphingomyelin/cholesterol liposomal vincristine: A new formulation for an old drug. Expert Opin Biol Ther 6(4):409-415.
22. Bedikian AY, Vardeleon A, Smith T, Campbell S, Namdari R. 2006. Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients. J Clin Pharmacol 46(7):727-737.
23. Sarris AH, Hagemeister F, Romaguera J, Rodriguez MA, McLaughlin P, Tsimberidou AM, Medeiros LJ, Samuels B, Pate O, Oholendt M, Kantarjian H, Burge C, Cabanillas F. 2000. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: Early results of an ongoing phase II trial. Ann Oncol 11(1):69-72.
24. Embree L, Gelmon K, Tolcher A, Hudon N, Heggie J, Dedhar C, Logan P, Bally MB, Mayer LD. 1998. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. Cancer Chemother Pharmacol 41(5):347-352.
25. Cattel L, Ceruti M, Dosio F. 2003. From conventional to stealth liposomes: A new frontier in cancer chemotherapy. Tumori 89(3):237-249.
26. Vail DM, Kurzman ID, Glawe PC, O'Brien MG, Chun R, Garrett LD, Obradovich JE, Fred RM, 3rd, Khanna C, Colbern GT, Working PK. 2002. Stealth liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: A randomized multicenter clinical trial. Cancer Chemother Pharmacol 50(2):131-136.
27. Takeuchi H, Kojima H, Yamamoto H, Kawashima Y. 2001. Evaluation of circulation profiles of liposomes coated with hydrophilic polymers having different molecular weights in rats. J Control Release 75(1-2):83-91.
28. Siegal T, Horowitz A, Gabizon A. 1995. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: Biodistribution and therapeutic efficacy. J Neurosurg 83(6):1029-1037.
29. Webb MS, Saxon D, Wong FM, Lim HJ, Wang Z, Bally MB, Choi LS, Cullis PR, Mayer LD. 1998. Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): Effects on the pharmacokinetics of liposomal vincristine. Biochim Biophys Acta 1372(2):272-282.
30. Zhu G, Oto E, Vaage J, Quinn Y, Newman M, Engbers C, Uster P. 1996. The effect of vincristine-polyanion complexes in stealth liposomes on pharmacokinetics, toxicity and anti tumor activity. Cancer Chemother Pharmacol 39(1-2):138-142.
31. Bangham AD, Standish MM, Watkins JC. 1965. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 13(1):238-252.
32. Bangham AD, Horne RW. 1964. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J Mol Biol 8:660-668.
33. Haran G, Cohen R, Bar LK, Barenholz Y. 1993. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1151(2):201-215.
34. Lasic DD, Frederik PM, Stuart MC, Barenholz Y, McIntosh TJ. 1992. Gelation of liposome interior: A novel method for drug encapsulation. FEBS Lett 312(2-3):255-258.
35. Mayer LD, Bally MB, Cullis PR. 1986. Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim Biophys Acta 857(1):123-126.
36. Needham D, Stoicheva N, Zhelev DV. 1997. Exchange of monooleoylphosphatidylcholine as monomer and micelle with membranes containing poly(ethylene glycol)-lipid. Biophys J 73(5):2615-2629.
37. Kenworthy AK, Hristova K, Needham D, McIntosh TJ. 1995. Range and magnitude of the steric pressure between bilayers containing phospholipids with covalently attached poly(ethylene glycol). Biophys J 68(5):1921-1936.
38. Ueda H, Ou D, Endo T, Nagase H, Tomono K, Nagai T. 1998. Evaluation of a sulfobutyl ether beta-cyclodextrin as a solubilizing/stabilizing agent for several drugs. Drug Dev Ind Pharm 24(9):863-867.
39. Zhigaltsev IV, Maurer N, Akhong QF, Leone R, Leng E, Wang J, Semple SC, Cullis PR. 2005. Liposome-encapsulated vincristine, vinblastine and vinorelbine: A comparative study of drug loading and retention. J Control Release 104(1):103-111.
40. Johnston MJ, Edwards K, Karlsson G, Cullis PR. 2008. Influence of drug-to-lipid ratio on drug release properties and liposome integrity in liposomal doxorubicin formulations. J Liposome Res 18(2):145-157.
41. Mayer LD, Harasym TO, Tardi PG, Harasym NL, Shew CR, Johnstone SA, Ramsay EC, Bally MB, Janoff AS. 2006. Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther 5(7):1854-1863.